TriSalus Life Sciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-39.2M | $-30.0M | $-59.4M | $-47.2M | $4.8M |
| Depreciation & Amortization | $626.0K | $744.0K | $684.0K | $398.0K | — |
| Depreciation | $600.0K | $700.0K | $700.0K | $276.0K | — |
| Amortization | — | — | $18.0K | $122.0K | — |
| Stock-Based Compensation | $9.1M | $5.4M | $1.4M | $368.0K | — |
| Net Cash from Operating Activities | $-18.0M | $-40.8M | $-50.6M | $-32.3M | $-1.7M |
| Investing Activities | |||||
| Capital Expenditures | $918.0K | $345.0K | $588.0K | $655.0K | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-838.0K | $-345.0K | $-1.6M | $-1.8M | $60.0K |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | $232.4M | — |
| Net Cash from Financing Activities | $30.8M | $37.9M | $54.6M | $13.5M | $544.0K |
| Net Change in Cash | $11.9M | $-3.3M | $2.5M | $-20.6M | $-1.1M |
| Free Cash Flow | $-18.9M | $-41.2M | $-51.2M | $-33.0M | — |